vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and ONESPAWORLD HOLDINGS Ltd (OSW). Click either name above to swap in a different company.
ONESPAWORLD HOLDINGS Ltd is the larger business by last-quarter revenue ($242.1M vs $183.1M, roughly 1.3× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 5.0%, a 8.4% gap on every dollar of revenue. On growth, ONESPAWORLD HOLDINGS Ltd posted the faster year-over-year revenue change (11.5% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $14.9M). Over the past eight quarters, ONESPAWORLD HOLDINGS Ltd's revenue compounded faster (7.1% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
AMPH vs OSW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $242.1M |
| Net Profit | $24.4M | $12.1M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 6.8% |
| Net Margin | 13.3% | 5.0% |
| Revenue YoY | -1.8% | 11.5% |
| Net Profit YoY | -35.7% | -16.2% |
| EPS (diluted) | $0.51 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $242.1M | ||
| Q3 25 | $191.8M | $258.5M | ||
| Q2 25 | $174.4M | $240.7M | ||
| Q1 25 | $170.5M | $219.6M | ||
| Q4 24 | $186.5M | $217.2M | ||
| Q3 24 | $191.2M | $241.7M | ||
| Q2 24 | $182.4M | $224.9M | ||
| Q1 24 | $171.8M | $211.2M |
| Q4 25 | $24.4M | $12.1M | ||
| Q3 25 | $17.4M | $24.3M | ||
| Q2 25 | $31.0M | $19.9M | ||
| Q1 25 | $25.3M | $15.3M | ||
| Q4 24 | $38.0M | $14.4M | ||
| Q3 24 | $40.4M | $21.6M | ||
| Q2 24 | $37.9M | $15.8M | ||
| Q1 24 | $43.2M | $21.2M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 6.8% | ||
| Q3 25 | 13.2% | 10.2% | ||
| Q2 25 | 24.2% | 9.2% | ||
| Q1 25 | 21.9% | 7.7% | ||
| Q4 24 | 24.2% | 7.9% | ||
| Q3 24 | 29.8% | 10.3% | ||
| Q2 24 | 30.3% | 8.4% | ||
| Q1 24 | 27.9% | 8.0% |
| Q4 25 | 13.3% | 5.0% | ||
| Q3 25 | 9.0% | 9.4% | ||
| Q2 25 | 17.8% | 8.3% | ||
| Q1 25 | 14.8% | 7.0% | ||
| Q4 24 | 20.4% | 6.6% | ||
| Q3 24 | 21.1% | 8.9% | ||
| Q2 24 | 20.8% | 7.0% | ||
| Q1 24 | 25.1% | 10.0% |
| Q4 25 | $0.51 | $0.12 | ||
| Q3 25 | $0.37 | $0.23 | ||
| Q2 25 | $0.64 | $0.19 | ||
| Q1 25 | $0.51 | $0.15 | ||
| Q4 24 | $0.74 | $0.13 | ||
| Q3 24 | $0.78 | $0.20 | ||
| Q2 24 | $0.73 | $0.15 | ||
| Q1 24 | $0.81 | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $16.3M |
| Total DebtLower is stronger | $608.7M | $84.0M |
| Stockholders' EquityBook value | $788.8M | $542.6M |
| Total Assets | $1.6B | $707.1M |
| Debt / EquityLower = less leverage | 0.77× | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $16.3M | ||
| Q3 25 | $276.2M | $29.6M | ||
| Q2 25 | $231.8M | $35.0M | ||
| Q1 25 | $236.9M | $22.6M | ||
| Q4 24 | $221.6M | $57.4M | ||
| Q3 24 | $250.5M | $48.8M | ||
| Q2 24 | $217.8M | $62.5M | ||
| Q1 24 | $289.6M | $65.4M |
| Q4 25 | $608.7M | $84.0M | ||
| Q3 25 | $608.6M | $85.2M | ||
| Q2 25 | $607.7M | $96.2M | ||
| Q1 25 | $603.9M | $97.4M | ||
| Q4 24 | $601.6M | $98.6M | ||
| Q3 24 | $596.4M | $98.7M | ||
| Q2 24 | $586.9M | $123.8M | ||
| Q1 24 | $594.0M | $138.6M |
| Q4 25 | $788.8M | $542.6M | ||
| Q3 25 | $776.7M | $552.8M | ||
| Q2 25 | $757.5M | $548.3M | ||
| Q1 25 | $751.3M | $530.6M | ||
| Q4 24 | $732.3M | $554.5M | ||
| Q3 24 | $727.7M | $540.1M | ||
| Q2 24 | $713.3M | $532.7M | ||
| Q1 24 | $672.4M | $515.5M |
| Q4 25 | $1.6B | $707.1M | ||
| Q3 25 | $1.7B | $732.6M | ||
| Q2 25 | $1.6B | $731.8M | ||
| Q1 25 | $1.6B | $708.7M | ||
| Q4 24 | $1.6B | $746.4M | ||
| Q3 24 | $1.5B | $734.0M | ||
| Q2 24 | $1.5B | $756.8M | ||
| Q1 24 | $1.6B | $763.6M |
| Q4 25 | 0.77× | 0.15× | ||
| Q3 25 | 0.78× | 0.15× | ||
| Q2 25 | 0.80× | 0.18× | ||
| Q1 25 | 0.80× | 0.18× | ||
| Q4 24 | 0.82× | 0.18× | ||
| Q3 24 | 0.82× | 0.18× | ||
| Q2 24 | 0.82× | 0.23× | ||
| Q1 24 | 0.88× | 0.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $20.0M |
| Free Cash FlowOCF − Capex | $24.6M | $14.9M |
| FCF MarginFCF / Revenue | 13.4% | 6.2% |
| Capex IntensityCapex / Revenue | 4.5% | 2.1% |
| Cash ConversionOCF / Net Profit | 1.35× | 1.65× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $68.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $20.0M | ||
| Q3 25 | $52.6M | $33.2M | ||
| Q2 25 | $35.6M | $20.3M | ||
| Q1 25 | $35.1M | $10.1M | ||
| Q4 24 | $29.0M | $16.6M | ||
| Q3 24 | $60.0M | $28.6M | ||
| Q2 24 | $69.1M | $18.7M | ||
| Q1 24 | $55.3M | $15.0M |
| Q4 25 | $24.6M | $14.9M | ||
| Q3 25 | $47.2M | $27.6M | ||
| Q2 25 | $25.0M | $17.6M | ||
| Q1 25 | $24.4M | $8.4M | ||
| Q4 24 | $16.6M | $13.2M | ||
| Q3 24 | $46.2M | $27.5M | ||
| Q2 24 | $63.1M | $17.6M | ||
| Q1 24 | $46.5M | $13.7M |
| Q4 25 | 13.4% | 6.2% | ||
| Q3 25 | 24.6% | 10.7% | ||
| Q2 25 | 14.3% | 7.3% | ||
| Q1 25 | 14.3% | 3.8% | ||
| Q4 24 | 8.9% | 6.1% | ||
| Q3 24 | 24.1% | 11.4% | ||
| Q2 24 | 34.6% | 7.8% | ||
| Q1 24 | 27.1% | 6.5% |
| Q4 25 | 4.5% | 2.1% | ||
| Q3 25 | 2.8% | 2.2% | ||
| Q2 25 | 6.1% | 1.1% | ||
| Q1 25 | 6.3% | 0.8% | ||
| Q4 24 | 6.7% | 1.5% | ||
| Q3 24 | 7.2% | 0.5% | ||
| Q2 24 | 3.3% | 0.5% | ||
| Q1 24 | 5.1% | 0.6% |
| Q4 25 | 1.35× | 1.65× | ||
| Q3 25 | 3.03× | 1.36× | ||
| Q2 25 | 1.15× | 1.02× | ||
| Q1 25 | 1.39× | 0.66× | ||
| Q4 24 | 0.76× | 1.15× | ||
| Q3 24 | 1.48× | 1.33× | ||
| Q2 24 | 1.82× | 1.19× | ||
| Q1 24 | 1.28× | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
OSW
| Services | $197.3M | 82% |
| Products | $44.8M | 18% |
